Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

NCT04790344 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Conditions Studied

Interventions

  • DEVICE Investigational LUX-Dx ICM Implant

Study Locations (20)

California

  • John Muir Medical Center — Concord
  • Scripps Memorial Hospital — La Jolla
  • VA Loma Linda — Loma Linda
  • Kaiser Permanenty Los Angeles Medical Center — Los Angeles
  • University of California - Irvine — Orange
  • San Diego Cardiac Center — San Diego
  • Cardiology Associates Medical Group — Ventura

Florida

  • The Cardiac and Vascular Institute — Gainesville
  • North Florida South Georgia VA — Gainesville
  • St. John's Center for Clinical Research (First Coast Heart and Vascular Center, PLLC) — Jacksonville
  • Village Heart and Vein Center — Lady Lake
  • Naples Heart and Rhythm — Naples
  • Sarasota Memorial Hospital — Sarasota

Georgia

  • Piedmont Augusta Hospital — Augusta
  • Augusta University — Augusta
  • Northside Hospital — Gainesville
  • Northeast Georgia Heart Center, Inc. — Gainesville

Alabama

  • Grandview Medical Center - Affinity Hospital, LLC — Birmingham
  • Mobile Infirmary — Mobile

Arkansas

  • Arrhythmia Research Group — Jonesboro

Trial Details

FieldValue
Enrollment Target 525 participants
Start Date 2021-03-20
Est. Completion 2026-06
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04790344

The ClinicalTrials.gov registry entry for NCT04790344 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which Investigational LUX-Dx ICM Implant is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04790344 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04790344 about?

NCT04790344 is a clinical study titled "LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.". The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

What is the current status of trial NCT04790344?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 525 participants. The study started on 2021-03-20. Estimated completion is 2026-06.

What conditions does trial NCT04790344 study?

This clinical trial studies the following conditions: Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04790344?

The interventions under investigation include: Investigational LUX-Dx ICM Implant (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04790344?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04790344 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial